EiPLA
Chemical compound
From Wikipedia, the free encyclopedia
EiPLA, also known as N-ethyl-N-isopropyllysergamide or as lysergic acid ethylisopropylamide, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).[2][3][1] It is an isomer of ETH-LAD.[1]
Other namesEiPLA; Ethylisopropyllysergamide; N-Ethyl-N-isopropyllysergamide; Lysergic acid ethylisopropylamide
Drug classSerotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
Legal status
- DE: NpSG (Industrial and scientific use only)
- UK: Under Psychoactive Substances Act
 | |
 | |
| Clinical data | |
|---|---|
| Other names | EiPLA; Ethylisopropyllysergamide; N-Ethyl-N-isopropyllysergamide; Lysergic acid ethylisopropylamide |
| Routes of administration | Oral[1] |
| Drug class | Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C21H27N3O |
| Molar mass | 337.467 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Use and effects
EiPLA has been identified in blotter containing doses of 86 to 97 μg base equivalent per tab.[1] Blotter containing 200 μg per tab has also been described.[1] Anecdotal reports suggest that EiPLA produces psychedelic effects but is less potent than LSD.[1]
Interactions
Pharmacology
Chemistry
History
EiPLA was first described in the scientific literature by David E. Nichols and colleagues by at least 1994.[2] It appears to have emerged as a novel designer drug by 2019.[1]